Pharmac Proposes Wider Access To A Treatment For People With A Rare Blood Cancer
Pharmac is consulting on a change that would allow brentuximab vedotin to be used as a first-line treatment option for people newly diagnosed with sALCL. If approved, the treatment would be funded from 1 April 2026.